1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Biomedical Engineering
  4. Volume 21, 2019
  5. Article

Annual Review of Biomedical Engineering

Volume 21, 2019

New Sensor and Wearable Technologies to Aid in the Diagnosis and Treatment Monitoring of Parkinson's Disease

Abstract

Parkinson's disease (PD) is a degenerative disorder of the brain characterized by the impairment of the nigrostriatal system. This impairment leads to specific motor manifestations (i.e., bradykinesia, tremor, and rigidity) that are assessed through clinical examination, scales, and patient-reported outcomes. New sensor-based and wearable technologies are progressively revolutionizing PD care by objectively measuring these manifestations and improving PD diagnosis and treatment monitoring. However, their use is still limited in clinical practice, perhaps because of the absence of external validation and standards for their continuous use at home. In the near future, these systems will progressively complement traditional tools and revolutionize the way we diagnose and monitor patients with PD.

Keyword(s): biomedical, movement disorders, Parkinson's disease, remote sensing technology, technological innovations, technology assessment, wearable electronic devices
Loading

Article metrics loading...

/content/journals/10.1146/annurev-bioeng-062117-121036
2019-06-04
2025-04-18
Loading full text...

Full text loading...

/deliver/fulltext/bioeng/21/1/annurev-bioeng-062117-121036.html?itemId=/content/journals/10.1146/annurev-bioeng-062117-121036&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Dorsey ER, Bloem BR. 2018. The Parkinson pandemic—a call to action. JAMA Neurol 75:9–10
     [Google Scholar]
  2. 2.
    Ehringer H, Hornykiewicz O. 1960. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system.]. Klin. Wochenschr. 4:53–57 In German )
     [Google Scholar]
  3. 3.
    Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR et al. 2013. EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease. Eur. J. Neurol. 20:16–34
     [Google Scholar]
  4. 4.
    Carroll LSL. 2017. A comprehensive definition of technology from an ethological perspective. Soc. Sci. 6:126
     [Google Scholar]
  5. 5.
    Van den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A et al. 2003. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 157:1015–22
     [Google Scholar]
  6. 6.
    Nussbaum RL, Ellis CE. 2003. Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. 348:1356–64
     [Google Scholar]
  7. 7.
    Gelb DJ, Oliver E, Gilman S 1999. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56:33–39
     [Google Scholar]
  8. 8.
    Postuma RB, Berg D, Stern M, Poewe W, Olanow CW et al. 2015. MDS clinical diagnostic criteria for Parkinson's disease. Mov. Disord. 30:1591–601
     [Google Scholar]
  9. 9.
    Oertel W, Schulz JB. 2016. Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J. Neurochem. 139:Suppl. 1325–37
     [Google Scholar]
  10. 10.
    Carlsson A, Lindqvist M, Magnusson T 1957. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200
     [Google Scholar]
  11. 11.
    Cotzias GC, Van Woert MH, Schiffer LM 1967. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 276:374–79
     [Google Scholar]
  12. 12.
    Cotzias GC, Papavasiliou PS, Gellene R 1969. l-dopa in Parkinson's syndrome. N. Engl. J. Med. 281:272
     [Google Scholar]
  13. 13.
    Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM 1969. Treatment of Parkinsonism with levodopa. Arch. Neurol. 21:343–54
     [Google Scholar]
  14. 14.
    Hughes AJ, Daniel SE, Blankson S, Lees AJ 1993. A clinicopathologic study of 100 cases of Parkinson's disease. Arch. Neurol. 50:140–48
     [Google Scholar]
  15. 15.
    Rajput AH, Rozdilsky B, Ang L 1991. Occurrence of resting tremor in Parkinson's disease. Neurology 41:1298–99
     [Google Scholar]
  16. 16.
    Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C et al. 1990. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. Neurology 40:1529–34
     [Google Scholar]
  17. 17.
    Schapira AHV, Chaudhuri KR, Jenner P 2017. Non-motor features of Parkinson disease. Nat. Rev. Neurosci. 18:435–50
     [Google Scholar]
  18. 18.
    Berg D, Postuma RB, Adler CH, Bloem BR, Chan P et al. 2015. MDS research criteria for prodromal Parkinson's disease. Mov. Disord. 30:1600–11
     [Google Scholar]
  19. 19.
    Siderowf A, Lang AE. 2012. Premotor Parkinson's disease: concepts and definitions. Mov. Disord. 27:608–16
     [Google Scholar]
  20. 20.
    Ross GW, Abbott RD, Petrovitch H, Tanner CM, White LR 2012. Pre-motor features of Parkinson's disease: the Honolulu–Asia Aging Study experience. Parkinsonism Relat. Disord. 18:S199–202
     [Google Scholar]
  21. 21.
    Berg D, Marek K, Ross GW, Poewe W 2012. Defining at-risk populations for Parkinson's disease: lessons from ongoing studies. Mov. Disord. 27:656–65
     [Google Scholar]
  22. 22.
    Coelho M, Ferreira JJ. 2012. Late-stage Parkinson disease. Nat. Rev. Neurol. 8:435–42
     [Google Scholar]
  23. 23.
    Hely MA, Morris JGL, Reid WGJ, Trafficante R 2005. Sydney Multicenter Study of Parkinson's disease: Non-l-dopa-responsive problems dominate at 15 years. Mov. Disord. 20:190–99
     [Google Scholar]
  24. 24.
    Chaudhuri KR, Poewe W, Brooks D 2018. Motor and nonmotor complications of levodopa: phenomenology, risk factors, and imaging features. Mov. Disord. 33:909–19
     [Google Scholar]
  25. 25.
    Fox SH, Lang AE. 2008. Levodopa-related motor complications—phenomenology. Mov. Disord. 23:Suppl. 3509–14
     [Google Scholar]
  26. 26.
    Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG 2007. Levodopa-induced dyskinesias. Mov. Disord. 22:1379–89
     [Google Scholar]
  27. 27.
    Péchevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C et al. 2005. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur. J. Neurol. 12:956–63
     [Google Scholar]
  28. 28.
    NICE (Natl. Inst. Health Care Excell.) 2017. Parkinson's disease in adults: diagnosis and management Guidel. NG71, NICE, Dep. Health London, UK: http://www.nice.org.uk/guidance/ng71
    [Google Scholar]
  29. 29.
    Seppi K, Schocke MFH. 2005. An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. Curr. Opin. Neurol. 18:370–75
     [Google Scholar]
  30. 30.
    Kuriakose R, Stoessl AJ. 2010. Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications. Prog. Brain Res. 184:C177–92
     [Google Scholar]
  31. 31.
    Parkinson J. 1817. An Essay on the Shaking Palsy London: Whittingham & Rowland
     [Google Scholar]
  32. 32.
    Lanska DJ, Goetz CG, Chmura TA 2001. Development of instruments for abnormal movements: dynamometers, the dynamograph, and tremor recorders. Part 9 of the MDS-sponsored History of Movement Disorders Exhibit, Barcelona, June 2000. Mov. Disord. 16:736–41
     [Google Scholar]
  33. 33.
    Lanska DJ, Goetz CG, Chmura TA 2001. Development of instruments for abnormal movements: postural sway and gait analyses. Part 10 of the MDS-sponsored History of Movement Disorders exhibit, Barcelona, June 2000. Mov. Disord. 16:742–48
     [Google Scholar]
  34. 34.
    Charcot J-M. 1892. [Vibratory therapeutics: the application of rapid and continuous vibrations to the treatment of certain diseases of the nervous system.]. Prog. Med. 16:149–51 In French )
     [Google Scholar]
  35. 35.
    Gowers WR. 1888. A Manual of Diseases of the Nervous System London: J. & A. Churchill
     [Google Scholar]
  36. 36.
    Boshes B, Norton AH. 1955. Graphic studies in tone and tremor: preliminary observations in the Parkinsonian state. Q. Bull. Northwest. Univ. Med. Sch. 29:314–25
     [Google Scholar]
  37. 37.
    Asai K, Hufschmidt HJ, Schaltenbrand G 1960. The passive muscle relaxation in parkinsonism: myographic studies of the pathophysiology of the rigor. J. Nerv. Ment. Dis. 130:449–55
     [Google Scholar]
  38. 38.
    Lance JW, Schwab RS, Peterson EA 1963. Action tremor and the cogwheel phenomenon in Parkinson's disease. Brain 86:95–110
     [Google Scholar]
  39. 39.
    Edwards AS. 1946. The finger tromometer. Am. J. Psychol. 59:273–83
     [Google Scholar]
  40. 40.
    Agate FJ Jr, Doshay LJ, Curtis FK. 1956. Quantitative measurement of therapy in paralysis agitans. JAMA 160:352–54
     [Google Scholar]
  41. 41.
    Cowell TK, Marsden CD, Owen DA 1965. Objective measurement of parkinsonian tremor. Lancet 2:1278–79
     [Google Scholar]
  42. 42.
    Fahn S, Elton R, Members of the UPDRS Development Committee. 1987. Unified Parkinson's Disease Rating Scale. Recent Developments in Parkinson's Disease, vol. 2 S Fahn, CD Mardsen, P Jenner, P Teychenne 153–63 Basingstoke, UK: Macmillan
     [Google Scholar]
  43. 43.
    Schwab R, England A. 1969. Projection technique for evaluating surgery in Parkinson's disease. Third Symposium on Parkinson's Disease FH Billingham, MC Donaldson 152–57 Edinburgh, UK: Livingstone
     [Google Scholar]
  44. 44.
    Bhidayasiri R, Martinez-Martin P. 2017. Clinical assessments in Parkinson's disease: scales and monitoring. Int. Rev. Neurobiol. 132:129–82
     [Google Scholar]
  45. 45.
    Hoehn MM, Yahr MD. 1967. Parkinsonism: onset, progression, and mortality. Neurology 17:427–42
     [Google Scholar]
  46. 46.
    Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT et al. 2004. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov. Disord. 19:1020–28
     [Google Scholar]
  47. 47.
    Ramaker C, Marinus J, Stiggelbout AM, van Hilten BJ 2002. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov. Disord. 17:867–76
     [Google Scholar]
  48. 48.
    Martinez-Martin P, Gil-Nagel A, Gracia LM, Balseiro Gomez J, Martinez-Sarries J et al. 1994. Unified Parkinson's disease rating scale characteristics and structure. Mov. Disord. 9:76–83
     [Google Scholar]
  49. 49.
    Stebbins GT, Goetz CG. 1998. Factor structure of the Unified Parkinson's Disease Rating Scale: Motor Examination section. Mov. Disord. 13:633–36
     [Google Scholar]
  50. 50.
    Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C et al. 2007. Movement Disorder Society–sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov. Disord. 22:41–47
     [Google Scholar]
  51. 51.
    Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S et al. 2008. Movement Disorder Society–sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23:2129–70
     [Google Scholar]
  52. 52.
    Richards M, Marder K, Cote L, Mayeux R 1994. Interrater reliability of the Unified Parkinson's Disease Rating Scale Motor Examination. Mov. Disord. 9:89–91
     [Google Scholar]
  53. 53.
    Bennett DA, Shannon KM, Beckett LA, Goetz GG, Wilson RS 1997. Metric properties of nurses’ ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale. Neurology 49:1580–87
     [Google Scholar]
  54. 54.
    Siderowf A, McDermott M, Kieburtz K, Blindauer K, Plumb S, Shoulson I 2002. Test–retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. Mov. Disord. 17:758–63
     [Google Scholar]
  55. 55.
    Hauser RA, Deckers F, Lehert P 2004. Parkinson's disease home diary: further validation amd implications for clinical trials. Mov. Disord. 19:1409–13
     [Google Scholar]
  56. 56.
    Papapetropoulos SS. 2012. Patient diaries as a clinical endpoint in Parkinson's disease clinical trials. CNS Neurosci. Ther. 18:380–87
     [Google Scholar]
  57. 57.
    Maetzler W, Klucken J, Horne M 2016. A clinical view on the development of technology-based tools in managing Parkinson's disease. Mov. Disord. 31:1263–71
     [Google Scholar]
  58. 58.
    Rovini E, Maremmani C, Cavallo F 2017. How wearable sensors can support Parkinson's disease diagnosis and treatment: a systematic review. Front. Neurosci. 11:555
     [Google Scholar]
  59. 59.
    Connolly BS, Lang AE. 2014. Pharmacological treatment of Parkinson disease: a review. JAMA 311:1670–83
     [Google Scholar]
  60. 60.
    Eur. Comm. 2014Technology readiness levels (TRL). HORIZON 2020–Work Programme 2014–2015 General Annexes. https://ec.europa.eu/research/participants/data/ref/h2020/wp/2014_2015/annexes/h2020-wp1415-annex-g-trl_en.pdf
  61. 61.
    Sánchez-Ferro Á, Elshehabi M, Godinho C, Salkovic D, Hobert MA et al. 2016. New methods for the assessment of Parkinson's disease (2005 to 2015): a systematic review. Mov. Disord. 31:1283–92
     [Google Scholar]
  62. 62.
    Aulet B. 2013. Disciplined Entrepreneurship: 24 Steps to a Successful Startup Oxford, UK: Wiley-Blackwell
     [Google Scholar]
  63. 63.
    Blank SG. 2006. The Four Steps to the Epiphany: Successful Strategies for Products That Win Lulu.com: Lulu Enterp. , 2nd ed..
     [Google Scholar]
  64. 64.
    Bently L, Sherman B. 2014. Intellectual Property Law Oxford, UK: Oxford Univ. Press. , 4th ed..
     [Google Scholar]
  65. 65.
    Krug S. 2014. Don't Make Me Think, Revisited: A Common Sense Approach to Web Usability London: Pearson. , 3rd ed..
     [Google Scholar]
  66. 66.
    Stamford JA, Schmidt PN, Friedl KE 2015. What engineering technology could do for quality of life in Parkinson's disease: a review of current needs and opportunities. IEEE J. Biomed. Health Inform. 19:1862–72
     [Google Scholar]
  67. 67.
    Del Din S, Godfrey A, Mazzà C, Lord S, Rochester L 2016. Free-living monitoring of Parkinson's disease: lessons from the field. Mov. Disord. 31:1293–313
     [Google Scholar]
  68. 68.
    Arroyo-Gallego T, Ledesma-Carbayo MJ, Butterworth I, Matarazzo M, Montero-Escribano P et al. 2018. Detecting motor impairment in early Parkinson's disease via natural typing interaction with keyboards: validation of the neuroQWERTY approach in an uncontrolled at-home setting. J. Med. Internet Res. 20:e89
     [Google Scholar]
  69. 69.
    Thompson M, Van den Bruel A 2012. Diagnostic Tests Toolkit Oxford, UK: Wiley-Blackwell
     [Google Scholar]
  70. 70.
    Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA et al. 2016. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open 6:e012799
     [Google Scholar]
  71. 71.
    Sánchez-Ferro Á, Matarazzo M, Martínez-Martín P, Martínez-Ávila JC, Gómez de la Cámara A et al. 2018. Minimal clinically important difference for UPDRS-III in daily practice. Mov. Disord. Clin. Pract. 5:448–50
     [Google Scholar]
  72. 72.
    Espay AJ, Bonato P, Nahab F, Maetzler W, Horak F et al. 2017. Technology in Parkinson disease: challenges and opportunities. Mov. Disord. 31:1272–82
     [Google Scholar]
  73. 73.
    Eur. Parliam 2017. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EE 2017 OJ L117/1.
  74. 74.
    FDA (US Food Drug Admin.) 2018. Overview of device regulation Report, FDA Washington, DC: https://www.fda.gov/medicaldevices/deviceregulationandguidance/overview/default.htm
    [Google Scholar]
  75. 75.
    Maak TG, Wylie JD. 2016. Medical device regulation: a comparison of the United States and the European Union. J. Am. Acad. Orthop. Surg. 24:537–43
     [Google Scholar]
  76. 76.
    Giuffrida JP, Riley DE, Maddux BN, Heldman DA 2009. Clinically deployable Kinesia technology for automated tremor assessment. Mov. Disord. 24:723–30
     [Google Scholar]
  77. 77.
    Farzanehfar P, Woodrow H, Braybrook M, McGregor S, Evans A et al. 2018. Objective measurement in routine care of people with Parkinson's disease improves outcomes. npj 4:10
     [Google Scholar]
  78. 78.
    Duncan S, Stewart T, Schneller MB, Godbole S, Cain K, Kerr J 2018. Convergent validity of ActiGraph and Actical accelerometers for estimating physical activity in adults. PLOS ONE 13:e0198587
     [Google Scholar]
  79. 79.
    Godwin A, Agnew M, Stevenson J 2009. Accuracy of inertial motion sensors in static, quasistatic, and complex dynamic motion. J. Biomech. Eng. 131:114501
     [Google Scholar]
  80. 80.
    Luinge HJ, Veltink PH. 2005. Measuring orientation of human body segments using miniature gyroscopes and accelerometers. Med. Biol. Eng. Comput. 43:273–82
     [Google Scholar]
  81. 81.
    Sabatini AM. 2011. Kalman-filter-based orientation determination using inertial/magnetic sensors: observability analysis and performance evaluation. Sensors 11:9182–206
     [Google Scholar]
  82. 82.
    Elble RJ, McNames J. 2016. Using portable transducers to measure tremor severity. Tremor Other Hyperkinet. Mov. 6:375
     [Google Scholar]
  83. 83.
    Caldas R, Mundt M, Potthast W, Buarque de Lima Neto F, Markert B 2017. A systematic review of gait analysis methods based on inertial sensors and adaptive algorithms. Gait Posture 57:204–10
     [Google Scholar]
  84. 84.
    Vienne A, Barrois RP, Buffat S, Ricard D, Vidal PP 2017. Inertial sensors to assess gait quality in patients with neurological disorders: a systematic review of technical and analytical challenges. Front. Psychol. 8:817
     [Google Scholar]
  85. 85.
    Kubota KJ, Chen JA, Little MA 2016. Machine learning for large-scale wearable sensor data in Parkinson's disease: concepts, promises, pitfalls, and futures. Mov. Disord. 31:1314–26
     [Google Scholar]
  86. 86.
    Godinho C, Domingos J, Cunha G, Santos AT, Fernandes RM et al. 2016. A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson's disease. J. Neuroeng. Rehabil. 13:24
     [Google Scholar]
  87. 87.
    Heldman DA, Espay AJ, LeWitt PA, Giuffrida JP 2014. Clinician versus machine: reliability and responsiveness of motor endpoints in Parkinson's disease. Parkinsonism Relat. Disord. 20:590–95
     [Google Scholar]
  88. 88.
    Pulliam CL, Heldman DA, Orcutt TH, Mera TO, Giuffrida JP, Vitek JL 2015. Motion sensor strategies for automated optimization of deep brain stimulation in Parkinson's disease. Parkinsonism Relat. Disord. 21:378–82
     [Google Scholar]
  89. 89.
    Griffiths RI, Kotschet K, Arfon S, Xu ZM, Johnson W et al. 2012. Automated assessment of bradykinesia and dyskinesia in Parkinson's disease. J. Parkinson's Dis. 2:47–55
     [Google Scholar]
  90. 90.
    Ossig C, Gandor F, Fauser M, Bosredon C, Churilov L et al. 2016. Correlation of quantitative motor state assessment using a kinetograph and patient diaries in advanced PD: data from an observational study. PLOS ONE 11:e0161559
     [Google Scholar]
  91. 91.
    Farzanehfar P, Horne M. 2017. Evaluation of the Parkinson's KinetiGraph in monitoring and managing Parkinson's disease. Expert Rev. Med. Devices 14:583–91
     [Google Scholar]
  92. 92.
    Tzallas AT, Tsipouras MG, Rigas G, Tsalikakis DG, Karvounis EC et al. 2014. PERFORM: a system for monitoring, assessment and management of patients with Parkinson's disease. Sensors 14:21329–57
     [Google Scholar]
  93. 93.
    Deuschl G, Bain P, Brin M 2008. Consensus statement of the Movement Disorder Society on tremor. Mov. Disord. 13:2–23
     [Google Scholar]
  94. 94.
    Elble R, Bain P, Forjaz MJ, Haubenberger D, Testa C et al. 2013. Task force report. Scales for screening and evaluating tremor: critique and recommendations. Mov. Disord. 28:1793–800
     [Google Scholar]
  95. 95.
    Haubenberger D, Abbruzzese G, Bain PG, Bajaj N, Benito-León J et al. 2016. Transducer-based evaluation of tremor. Mov. Disord. 31:1327–36
     [Google Scholar]
  96. 96.
    Pulliam CL, Eichenseer SR, Goetz CG, Waln O, Hunter CB et al. 2014. Continuous in-home monitoring of essential tremor. Parkinsonism Relat. Disord. 20:37–40
     [Google Scholar]
  97. 97.
    Caligiuri MP. 1994. Portable device for quantifying parkinsonian wrist rigidity. Mov. Disord. 9:57–63
     [Google Scholar]
  98. 98.
    Prochazka A, Bennett DJ, Stephens MJ, Patrick SK, Sears-Duru R et al. 1997. Measurement of rigidity in Parkinson's disease. Mov. Disord. 12:24–32
     [Google Scholar]
  99. 99.
    Fasano A, Canning CG, Hausdorff JM, Lord S, Rochester L 2017. Falls in Parkinson's disease: a complex and evolving picture. Mov. Disord. 32:1524–36
     [Google Scholar]
  100. 100.
    Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ 2002. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:861–70
     [Google Scholar]
  101. 101.
    Bloem BR, Marinus J, Almeida Q, Dibble L, Nieuwboer A et al. 2016. Measurement instruments to assess posture, gait, and balance in Parkinson's disease: critique and recommendations. Mov. Disord. 31:1342–55
     [Google Scholar]
  102. 102.
    Iluz T, Gazit E, Herman T, Sprecher E, Brozgol M et al. 2014. Automated detection of missteps during community ambulation in patients with Parkinson's disease: a new approach for quantifying fall risk in the community setting. J. Neuroeng. Rehabil. 11:48
     [Google Scholar]
  103. 103.
    Dijkstra B, Kamsma Y, Zijlstra W 2010. Detection of gait and postures using a miniaturised triaxial accelerometer–based system: accuracy in community-dwelling older adults. Age Ageing 39:259–62
     [Google Scholar]
  104. 104.
    Adame MR, Al-Jawad A, Romanovas M, Hobert MA, Maetzler W et al. 2012. TUG test instrumentation for Parkinson's disease patients using inertial sensors and dynamic time warping. Biomed. Eng. 57:1071–74
     [Google Scholar]
  105. 105.
    van Lummel RC, Walgaard S, Hobert MA, Maetzler W, Van Dieën JH et al. 2016. Intra-rater, inter-rater and test–retest reliability of an instrumented Timed Up and Go (iTUG) test in patients with Parkinson's disease. PLOS ONE 11:e0151881
     [Google Scholar]
  106. 106.
    McDonough AL, Batavia M, Chen FC, Kwon S, Ziai J 2001. The validity and reliability of the GAITRite system's measurements: a preliminary evaluation. Arch. Phys. Med. Rehabil. 82:419–25
     [Google Scholar]
  107. 107.
    Menz HB, Latt MD, Tiedemann A, Kwan MMS, Lord SR 2004. Reliability of the GAITRite® walkway system for the quantification of temporo-spatial parameters of gait in young and older people. Gait Posture 20:20–25
     [Google Scholar]
  108. 108.
    Chien SL, Lin SZ, Liang CC, Soong YS, Lin SH et al. 2006. The efficacy of quantitative gait analysis by the GAITRite system in evaluation of parkinsonian bradykinesia. Parkinsonism Relat. Disord. 12:438–42
     [Google Scholar]
  109. 109.
    Pham MH, Elshehabi M, Haertner L, Del Din S, Srulijes K et al. 2017. Validation of a step detection algorithm during straight walking and turning in patients with Parkinson's disease and older adults using an inertial measurement unit at the lower back. Front. Neurol. 8:457
     [Google Scholar]
  110. 110.
    Mancini M, Horak FB. 2016. Potential of APDM mobility lab for the monitoring of the progression of Parkinson's disease. Expert Rev. Med. Devices 13:455–62
     [Google Scholar]
  111. 111.
    Evenson KR, Wen F, Metzger JS, Herring AH 2015. Physical activity and sedentary behavior patterns using accelerometry from a national sample of United States adults. Int. J. Behav. Nutr. Phys. Act. 12:20
     [Google Scholar]
  112. 112.
    Palmerini L, Rocchi L, Mellone S, Valzania F, Chiari L 2011. Feature selection for accelerometer-based posture analysis in Parkinson's disease. IEEE Trans. Neural Syst. Rehabil. Eng. 15:481–90
     [Google Scholar]
  113. 113.
    Mellone S, Tacconi C, Chiari L 2012. Gait and posture validity of a smartphone-based instrumented Timed Up and Go. Gait Posture 36:163–65
     [Google Scholar]
  114. 114.
    Fahn S. 1992. Adverse effects of levodopa. The Scientific Basis for the Treatment of Parkinson's Disease C Olanow, A Lieberman 89–112 Carnforth, UK: Parthenon
     [Google Scholar]
  115. 115.
    Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM et al. 2013. Which dyskinesia scale best detects treatment response?. Mov. Disord. 28:341–46
     [Google Scholar]
  116. 116.
    Ossig C, Antonini A, Buhmann C, Classen J, Csoti I et al. 2016. Wearable sensor–based objective assessment of motor symptoms in Parkinson's disease. J. Neural Transm. 123:57–64
     [Google Scholar]
  117. 117.
    Horne M, Kotschet K, McGregor S 2016. The clinical validation of objective measurement of movement in Parkinson's disease. Oruen 2:16–23
     [Google Scholar]
  118. 118.
    Mera TO, Burack MA, Giuffrida JP 2013. Objective motion sensor assessment highly correlated with scores of global levodopa-induced dyskinesia in Parkinson's disease. J. Parkinson's Dis. 3:399–407
     [Google Scholar]
  119. 119.
    Pulliam CL, Burack MA, Heldman DA, Giuffrida JP, Mera TO 2014. Motion sensor dyskinesia assessment during activities of daily living. J. Parkinson's Dis. 4:609–15
     [Google Scholar]
  120. 120.
    Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D et al. 2012. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 27:349–56
     [Google Scholar]
  121. 121.
    Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F et al. 2007. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov. Disord. 22:1901–11
     [Google Scholar]
  122. 122.
    Shulman LM, Taback RL, Rabinstein AA, Weiner WJ 2002. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 8:193–97
     [Google Scholar]
  123. 123.
    Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH et al. 2014. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 26:Suppl. 342–80
     [Google Scholar]
  124. 124.
    Klingelhoefer L, Jitkritsadakul O. 2017. Objective measurement and monitoring of nonmotor symptoms in Parkinson's disease. Int. Rev. Neurobiol. 133:347–87
     [Google Scholar]
  125. 125.
    Bhidayasiri R, Sringean J, Thanawattano C 2016. Sensor-based evaluation and treatment of nocturnal hypokinesia in Parkinson's disease: an evidence-based review. Parkinsonism Relat. Disord. 22:S127–33
     [Google Scholar]
  126. 126.
    McGregor S, Churchward P, Soja K, O'Driscoll D, Braybrook M et al. 2018. The use of accelerometry as a tool to measure disturbed nocturnal sleep in Parkinson's disease. npj 4:1
     [Google Scholar]
  127. 127.
    Ng KG, Ting CM, Yeo JH, Sim KW, Peh WL et al. 2004. Progress on the development of the MediWatch ambulatory blood pressure monitor and related devices. Blood Press. Monit. 9:149–65
     [Google Scholar]
  128. 128.
    Picardi C, Cosgrove J, Smith SL, Jamieson S, Alty J 2017. Objective assessment of cognitive impairment in Parkinson's disease using evolutionary algorithm. Proceedings of the 2017 European Conference on the Applications of Evolutionary Computation (EvoApplications 2017) G Squillero, K Sim 109–24 Cham, Switz: Springer Int.
     [Google Scholar]
  129. 129.
    Merriaux P, Dupuis Y, Boutteau R, Vasseur P, Savatier X 2017. A study of Vicon system positioning performance. Sensors 17:1591
     [Google Scholar]
  130. 130.
    McCandless PJ, Evans BJ, Janssen J, Selfe J, Churchill A, Richards J 2016. Effect of three cueing devices for people with Parkinson's disease with gait initiation difficulties. Gait Posture 44:7–11
     [Google Scholar]
  131. 131.
    Sofuwa O, Nieuwboer A, Desloovere K, Willems A-M, Chavret F, Jonkers I 2005. Quantitative gait analysis in Parkinson's disease: comparison with a healthy control group. Arch. Phys. Med. Rehabil. 86:1007–13
     [Google Scholar]
  132. 132.
    Mancini M, Zampieri C, Carlson-Kuhta P, Chiari L, Horak FB 2009. Anticipatory postural adjustments prior to step initiation are hypometric in untreated Parkinson's disease: an accelerometer-based approach. Eur. J. Neurol. 16:1028–34
     [Google Scholar]
  133. 133.
    Tucha O, Mecklinger L, Thome J, Reiter A, Alders GL et al. 2006. Kinematic analysis of dopaminergic effects on skilled handwriting movements in Parkinson's disease. J. Neural Transm. 113:609–23
     [Google Scholar]
  134. 134.
    Costa J, González HA, Valldeoriola F, Gaig C, Tolosa E, Valls-Solé J 2010. Nonlinear dynamic analysis of oscillatory repetitive movements in Parkinson's disease and essential tremor. Mov. Disord. 25:2577–86
     [Google Scholar]
  135. 135.
    Van Someren EJW, Vonk BFM, Thijssen WA, Speelman JD, Schuurman PR et al. 1998. A new actigraph for long-term registration of the duration and intensity of tremor and movement. IEEE Trans. Biomed. Eng. 45:386–95
     [Google Scholar]
  136. 136.
    Lebel K, Boissy P, Nguyen H, Duval C 2017. Inertial measurement systems for segments and joints kinematics assessment: towards an understanding of the variations in sensors accuracy. Biomed. Eng. Online 16:56
     [Google Scholar]
  137. 137.
    Fenney A, Jog MS, Duval C 2008. Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea. Clin. Neurol. Neurosurg. 110:160–67
     [Google Scholar]
  138. 138.
    Chaudhuri KR, Schapira AH, Politis M, Carr H, Loehrer P et al. 2009. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8:464–74
     [Google Scholar]
  139. 139.
    Dhawan V, Dhoat S, Williams AJ, DiMarco A, Pal S et al. 2006. The range and nature of sleep dysfunction in untreated Parkinson's disease (PD): a comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography. J. Neurol. Sci. 248:158–62
     [Google Scholar]
  140. 140.
    Peeraully T, Yong MH, Chokroverty S, Tan EK 2012. Sleep and Parkinson's disease: a review of case-control polysomnography studies. Mov. Disord. 27:1729–37
     [Google Scholar]
  141. 141.
    Klingelhoefer L, Rizos A, Sauerbier A, McGregor S, Martinez-Martin P et al. 2016. Night-time sleep in Parkinson's disease—the potential use of Parkinson's KinetiGraph: a prospective comparative study. Eur. J. Neurol. 23:1275–88
     [Google Scholar]
  142. 142.
    Goetz CG, Stebbins GT, Wolff D, DeLeeuw W, Bronte-Stewart H et al. 2009. Testing objective measures of motor impairment in early Parkinson's disease: feasibility study of an at-home testing device. Mov. Disord. 24:551–56
     [Google Scholar]
  143. 143.
    Patel S, Chen B-R, Buckley T, Rednic R, McClure D et al. 2010. Home monitoring of patients with Parkinson's disease via wearable technology and a web-based application. Proceedings of the 2010 Annual International Conference of the IEEE Engineering in Medicine and Biology Society4411–14 Piscataway, NJ: IEEE
     [Google Scholar]
  144. 144.
    Roy SH, Cole BT, Gilmore LD, De Luca CJ, Nawab SH 2011. Resolving signal complexities for ambulatory monitoring of motor function in Parkinson's disease. Proceedings of the 2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society4836–39 Piscataway, NJ: IEEE
     [Google Scholar]
  145. 145.
    Roy SH, Cole BT, Gilmore LD, De Luca CJ, Thomas CA et al. 2013. High-resolution tracking of motor disorders in Parkinson's disease during unconstrained activity. Mov. Disord. 28:1080–87
     [Google Scholar]
  146. 146.
    Giancardo L, Sánchez-Ferro A, Arroyo-Gallego T, Butterworth I, Mendoza CS et al. 2016. Computer keyboard interaction as an indicator of early Parkinson's disease. Sci. Rep. 6:34468
     [Google Scholar]
  147. 147.
    Arroyo-Gallego T, Ledesma-Carbayo MJ, Sánchez-Ferro A, Butterworth I, Mendoza CS et al. 2017. Detection of motor impairment in Parkinson's disease via mobile touchscreen typing. IEEE Trans. Biomed. Eng. 64:1994–2002
     [Google Scholar]
  148. 148.
    Matias R, Paixão V, Bouça R, Ferreira JJ 2017. A perspective on wearable sensor measurements and data science for Parkinson's disease. Front. Neurol. 8:677
     [Google Scholar]
  149. 149.
    Dorsey ER, Vlaanderen FP, Engelen LJLPG, Kieburtz K, Zhu W et al. 2016. Moving Parkinson care to the home. Mov. Disord. 31:1258–62
     [Google Scholar]
  150. 150.
    Shull PB, Jirattigalachote W, Hunt MA, Cutkosky MR, Delp SL 2014. Quantified self and human movement: a review on the clinical impact of wearable sensing and feedback for gait analysis and intervention. Gait Posture 40:11–19
     [Google Scholar]
  151. 151.
    Mera TO, Heldman DA, Espay AJ, Payne M, Giuffrida JP 2012. Feasibility of home-based automated Parkinson's disease motor assessment. J. Neurosci. Methods 203:152–56
     [Google Scholar]
  152. 152.
    Fisher JM, Hammerla NY, Rochester L, Andras P, Walker RW 2016. Body-worn sensors in Parkinson's disease: evaluating their acceptability to patients. Telemed. e-Health 22:63–69
     [Google Scholar]
  153. 153.
    Bergmann JHM, Chandaria V, McGregor A 2012. Wearable and implantable sensors: the patient's perspective. Sensors 12:16695–709
     [Google Scholar]
  154. 154.
    Shull PB, Silder A, Shultz R, Dragoo JL, Besier TF et al. 2013. Six-week gait retraining program reduces knee adduction moment, reduces pain, and improves function for individuals with medial compartment knee osteoarthritis. J. Orthop. Res. 31:1020–25
     [Google Scholar]
  155. 155.
    Jellish J, Abbas JJ, Ingalls TM, Mahant P, Samanta J et al. 2015. A system for real-time feedback to improve gait and posture in Parkinson's disease. IEEE J. Biomed. Health Inform. 19:1809–19
     [Google Scholar]
  156. 156.
    Arora S, Venkataraman V, Zhan A, Donohue S, Biglan KM et al. 2015. Detecting and monitoring the symptoms of Parkinson's disease using smartphones: a pilot study. Parkinsonism Relat. Disord. 21:650–53
     [Google Scholar]
  157. 157.
    Bot BM, Suver C, Neto EC, Kellen M, Klein A et al. 2016. The mPower study, Parkinson disease mobile data collected using ResearchKit. Sci. Data 3:160011
     [Google Scholar]
  158. 158.
    Lipsmeier F, Taylor KI, Kilchenmann T, Wolf D, Scotland A et al. 2018. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial. Mov. Disord. 33:1287–97
     [Google Scholar]
  159. 159.
    Linares-del Rey M, Vela-Desojo L, Cano-de la Cuerda R 2017. Aplicaciones móviles en la enfermedad de Parkinson: una revisión sistemática. Neurología 66:213–29
     [Google Scholar]
  160. 160.
    Lakshminarayana R, Wang D, Burn D, Chaudhuri KR, Galtrey C et al. 2017. Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson's disease. npj 3:2
     [Google Scholar]
/content/journals/10.1146/annurev-bioeng-062117-121036
Loading
New Sensor and Wearable Technologies to Aid in the Diagnosis and Treatment Monitoring of Parkinson's Disease
Annual Review of Biomedical Engineering 21, 111 (2019); https://doi.org/10.1146/annurev-bioeng-062117-121036
/content/journals/10.1146/annurev-bioeng-062117-121036
/content/journals/10.1146/annurev-bioeng-062117-121036
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error